QualityStocksNewsBreaks Archives - Page 84 of 1419

TuesdayJan 14, 2025 8:45 am

QualityStocksNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company focused on neurological disorders, has received a Notification to Grant Patent Right for its Chinese invention patent application (No: 2020800553323). The patent covers compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, including autism, using a novel intranasal suramin formulation. CEO Howard Weisman highlighted this as a historic milestone, marking the first intellectual property protection for suramin in over a century. PaxMedica plans to pursue similar protections in additional jurisdictions, including the United States. To view the full press release, visit https://ibn.fm/sn3b4 About PaxMedica Inc. PaxMedica is a forward-looking,…

TuesdayJan 14, 2025 7:35 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites," has been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting, April 25-30, 2025, in Chicago. The presentation will highlight Calidi’s proprietary RTNova systemic platform, which leverages a novel vaccinia virus strain enveloped with a human cell membrane to overcome immune system elimination, enabling targeted delivery to multiple metastatic tumor sites. This innovative approach aims to address treatment challenges in advanced metastatic cancers, such as lung cancer, where…

TuesdayJan 14, 2025 7:30 am

QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Refutes NVIDIA CEO’s Quantum Computing Comments on CNBC

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced that CEO Dr. Alan Baratz appeared on CNBC’s “The Exchange” on January 8th to address recent comments by NVIDIA CEO Jensen Huang regarding quantum computing’s readiness. Dr. Baratz clarified that D-Wave’s annealing quantum computing systems are already commercially available and solving real-world problems, unlike gate-model quantum computers, which may still face significant development timelines. He highlighted D-Wave’s success in optimization problems, such as materials simulations, and emphasized the company’s work with a multitude of customers that are using D-Wave technology today to solve complex…

MondayJan 13, 2025 2:56 pm

QualityStocksNewsBreaks – Adageis’s Platform Empowering Organizations to Adjust to New Risk-Scoring Dynamics

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is in support of the Centers for Medicare and Medicaid Services’ (“CMS”) switching from the V24 to the V28 upgrade of the Hierarchical Condition Categories (“HCC”) model. “The transition from CMS-HCC V24 to V28 reflects a critical update to the risk adjustment model used in Medicare Advantage… The more precise structure enhances diagnostic specificity, allowing for better patient categorization. This change supports value-based care by tying payments more closely to actual patient needs,” reads a recent article. “The CMS-HCC transition aligns closely with Adageis’s mission of…

MondayJan 13, 2025 1:48 pm

QualityStocksNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Eyes Opportunity in Race to Establish AI Sector Infrastructure

McEwen Mining (NYSE: MUX) (TSX: MUX) was highlighted in a recent article that discussed favorable positioning of the United States in the AI sector. “Sam Altman, the CEO of OpenAI, has voiced his confidence in President-elect Donald Trump supporting the AI sector and ensuring that America, together with its allies, retain pole position in this nascent industry. Altman was speaking during a recent interview with Fox News,” the publication reads. “During the interview, Altman highlighted the need for support in the form of massive infrastructure… for the U.S. to stamp its leadership on AI technology and AI capabilities.” “Tech giants like…

MondayJan 13, 2025 11:10 am

QualityStocksNewsBreaks – ROTH Adds Five Strategic Hires to Its Sales and Trading Team

Roth Capital Partners, LLC (“ROTH”) has announced the expansion of its sales and trading team with five seasoned professionals: Todd Trimmer, Nathan Cahill, Ken Hawkins, Matthew Job, and Michael Shea. “These strategic hires exemplify ROTH’s commitment to expanding teams of professionals across departments and advancing our mission to deliver unparalleled service, innovation and growth for clients and stakeholders alike,” said Sagar Sheth, CEO of ROTH, highlighting the significance of these additions. To view the full press release, visit https://ibn.fm/Gp5aV About ROTH ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Its full-service platform provides capital…

MondayJan 13, 2025 7:30 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and expenses. The offering, exclusively placed by Ladenburg Thalmann & Co. Inc., is set to close on or around Jan. 10, 2025, subject to customary conditions. Proceeds will support working capital and general corporate purposes. The shares are offered under an effective Form S-3 registration statement, with a final prospectus available on the SEC's website or through Ladenburg Thalmann. To view…

FridayJan 10, 2025 1:45 pm

QualityStocksNewsBreaks – AEON Biopharma Inc. (NYSE: AEON) Secures $20M in Underwritten Public Offering

AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, has announced the closing of its firm commitment underwritten public offering. AEON secured approximately $20.0 million in gross proceeds from the offering, of which it intends to use the net, together with its existing cash, for general corporate purposes and working capital. As detailed in the announcement, the company granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or warrants to cover over-allotments, if any. On Jan. 7, Aegis exercised its over-allotment option with respect…

WednesdayJan 08, 2025 3:07 pm

QualityStocksNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Expanding Exploration, Looks to Replicate Success of Flagship Project

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a junior exploration company, is positioned to play a critical role amidst growth of copper and gold sectors. “The company’s flagship project, the Storm Copper Project, a joint initiative by Aston Bay and American West Metals, in Nunavut, Canada, made significant advancements in 2024 and is poised for further progress in 2025,” reads a recent article. “The Storm Copper Project has gained attention for its promising assay results and high-grade copper mineralization. Spring/summer 2024 marked another successful exploration season that identified extensive copper zones, demonstrating the project’s potential as a major contributor to global…

WednesdayJan 08, 2025 2:22 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

Site Search

Company Search

Category: QualityStocksNewsBreaks